Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Survival, Costs with First-Line Pazopanib Studied

Adv Ther; 2017 Nov; Vogelzang, Pal, Ghate, et al

Elderly patients with renal cell carcinoma (RCC) treated with first-line pazopanib survived longer than those who received sunitinib, according to an analysis involving >1,000 individuals. Pazopanib treatment also resulted in lower costs and utilization. Participants with RCC were ≥65 years of age and started first-line treatment with either pazopanib (n=522) or sunitinib (n=522). Investigators looked at overall survival, costs, and utilization. Among the results:

  • The group taking pazopanib survived an average of 18.2 months, vs 14.6 months in the contingent receiving sunitinib.
  • All-cause costs were ~$8,800 and ~$10,400, respectively.
  • Inpatient costs were ~$1,500 and ~$2,500, respectively.
  • Inpatient admissions and lengths of inpatient stay were lower in the pazopanib group.
Citation:

Vogelzang N, Pal S, Ghate S, et al. Clinical and economic outcomes in elderly advanced renal cell carcinoma patients starting pazopanib or sunitinib treatment: A retrospective Medicare claims analysis. Adv Ther. 2017;34(11):2452-2465. doi:10.1007/s12325-017-0628-2.

This Week's Must Reads

Overall survival factor in metastatic ccRCC, Thiery-Vuillemin A et al. Clinical Genitourinary Cancer 2018; 16: e297-e305

High perirenal fat thickness predicts poor progression-free survival in patients with localized ccRCC, Huang H et al. Urologic Oncology: Seminars and Original Investigations 2018; 36: 157.e1-157.e6

AXL linked to worse outcome of metastatic RCCs treated with sunitinib, Zucca L E et al. Urologic Oncology: Seminars and Original Investigations 2018: 36; 11.e13-11.e21

Pathologic predictors in lymph node dissection of metastatic RCC, Chipollini J et al. Clinical Genitourinary Cancer 2018; 16: Pages e443-450.

Plated-lymphocyte ratio is correlated with poor prognosis in RCC, Wang Z et al. Clinica Chimica Acta; 2018; 480: 166-72.

Must Reads in Renal Cell Carcinoma

Overall survival factor in metastatic ccRCC, Thiery-Vuillemin A et al. Clinical Genitourinary Cancer 2018; 16: e297-e305

High perirenal fat thickness predicts poor progression-free survival in patients with localized ccRCC, Huang H et al. Urologic Oncology: Seminars and Original Investigations 2018; 36: 157.e1-157.e6

AXL linked to worse outcome of metastatic RCCs treated with sunitinib, Zucca L E et al. Urologic Oncology: Seminars and Original Investigations 2018: 36; 11.e13-11.e21

Pathologic predictors in lymph node dissection of metastatic RCC, Chipollini J et al. Clinical Genitourinary Cancer 2018; 16: Pages e443-450.

Plated-lymphocyte ratio is correlated with poor prognosis in RCC, Wang Z et al. Clinica Chimica Acta; 2018; 480: 166-72.